Clinical, Cellular, and Molecular Effects of Corticosteroids on the Response to Intradermal Lipopolysaccharide Administration in Healthy Volunteers

Thomas P. Buters¹,², Pieter W. Hameeteman¹, Iris M.E. Jansen¹, Floris C. van Hindevoort¹, Wouter ten Voorde¹,², Hendrika W. Grievenk¹, Mascha Schoonakker¹, Marieke L. de Kam¹, Derek W. Gilroy³, Gary Feiss⁴, Robert Rissmann¹,²,⁵, Manon A.A. Jansen¹, Jacobus Burggraaf⁴,²,⁵ and Matthijs Moerland¹,²,*

The intradermal lipopolysaccharide (LPS) challenge in healthy volunteers has proven to be a valuable tool to study local inflammation in vivo. In the current study the inhibitory effects of oral and topical corticosteroid treatment on intradermal LPS responses were evaluated to benchmark the challenge for future investigational drugs. Twenty-four healthy male volunteers received a two-and-a-half-day twice daily (b.i.d.) pretreatment with topical clobetasol propionate 0.05% and six healthy volunteers received a two-and-a-half-day b.i.d. pretreatment with oral prednisolone at 0.25 mg/kg body weight per administration. Participants received one injection regimen of either 0, 2, or 4 intradermal LPS injections (5 ng LPS in 50 µL 0.9% sodium chloride solution). The LPS response was evaluated by noninvasive (perfusion, skin temperature, and erythema) and invasive assessments (cellular and cytokine responses) in suction blister exudate. Both corticosteroids significantly suppressed the clinical inflammatory response (erythema $P = 0.0001$ for clobetasol and $P = 0.0016$ for prednisolone; heat $P = 0.0245$ for clobetasol, perfusion $P < 0.0001$ for clobetasol and $P = 0.0036$ for prednisolone). Clobetasol also significantly reduced the number of monocytes subsets, dendritic cells, natural killer cells, and T cells in blister exudate. A similar effect was observed for prednisolone.

No relevant corticosteroid effects were observed on the cytokine response to LPS. We successfully demonstrated that the anti-inflammatory effects of corticosteroids can be detected using our intradermal LPS challenge model, validating it for evaluation of future investigational drugs, as an initial assessment of the anti-inflammatory effects of such compounds in a minimally invasive manner.

Study Highlights

**WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?**
☑️ In humans, intradermal lipopolysaccharide (LPS) administration causes an acute, localized, and transient inflammatory reaction that is safe and well tolerated. As such, the intradermal LPS challenge may be a valuable model for human clinical pharmacology studies.

**WHAT QUESTION DID THIS STUDY ADDRESS?**
☑️ This study evaluated the inhibitory effect of known potent anti-inflammatory drugs (topical and systemic corticosteroids) on the LPS-induced dermal inflammatory response.

**WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?**
☑️ This is the first study that thoroughly benchmarks the intradermal LPS model with known anti-inflammatory drugs. Importantly, based on the model, observations were made that may change the mechanistic thinking on corticosteroid effects in inflammatory skin diseases.

**HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?**
☑️ Our findings support the use of the intradermal LPS model for future proof of mechanism studies on anti-inflammatory compounds.

¹Centre for Human Drug Research, Leiden, The Netherlands; ²Leiden University Medical Centre, Leiden, The Netherlands; ³Division of Medicine, Centre for Clinical Pharmacology and Therapeutics, University College London, London, UK; ⁴Cutanea Life Sciences, Wayne, Pennsylvania, USA; ⁵Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands. *Correspondence: Matthijs Moerland (mmoerland@chdr.nl)

[Correction added on 18 January 2022, after first online publication: The author name Pieter Hameeteman has been corrected to Pieter W. Hameeteman in this version.]

Received September 21, 2021; accepted December 12, 2021. doi:10.1002/cpt.2516
One of the major hurdles in anti-inflammatory drug development is the translation of preclinical findings into early clinical studies, mainly because the huge differences in immune system between animals and humans. Further, healthy volunteers only sporadically suffer from inflammatory conditions and therefore the pharmacological target of novel investigational medicinal products are not activated or expressed. That is why commonly inflammatory challenge models are required for the evaluation of anti-inflammatory drugs in healthy volunteers. One of the best known and widely used challenge models is the intravenous lipopolysaccharide (LPS) challenge.\(^1\)\(^2\) Although intravenous LPS challenge has been proven to be valuable in clinical pharmacology and human physiology studies, it has several limitations. Firstly, intravenous LPS elicits primarily a systemic inflammatory response, meaning that the model is less suitable for measuring local effects of anti-inflammatory investigational compounds in peripheral tissues.\(^2\) Though there are contributions from peripheral tissues to the systemic inflammatory response, it is difficult to assess the exact role of the microvasculature or stromal cells in the intravenous LPS challenge model. Secondly, exposure to systemic LPS leads to a prolonged state of immunological hyporesponsiveness to LPS due to innate memory which hampers the possibility of rechallenging the same individual.\(^3\)\(^4\) We and others have published a local inflammatory challenge with intradermal LPS.\(^5\)\(^6\) In our comprehensive characterization we showed that intradermal administration of 5 ng of LPS induces a transient local inflammatory response, characterized by an increase in local perfusion, heat, erythema, immune cell attraction, and cytokine production.\(^7\) As a next step, we conducted a study evaluating the effects of corticosteroid treatment on the LPS-driven inflammatory response of the skin in healthy volunteers to validate our previously established intradermal LPS model. Corticosteroids were selected as these drugs have been used for more than 70 years as topical or oral treatment for inflammatory skin diseases. Surprisingly, systematic evaluations of the specific dermal anti-inflammatory activities of corticosteroids are not readily available in the public domain, let alone data on the effect sizes of the suppression. There is evidence that corticosteroids exert different anti-inflammatory effects in the systemic blood compartment than in peripheral tissue.\(^7\)\(^8\) For our study we selected topical clobetasol propionate 0.05% and oral prednisolone, allowing a differentiation between the anti-inflammatory effects of systemic and local treatment.

### MATERIALS AND METHODS

This study was conducted from October 2018 to January 2019 at the Centre for Human Drug Research (CHDR) and according to the Dutch Act on Medical Research involving Human Subjects (WMO). The study protocol was registered in the EudraCT database (number 2018-005510-41). The study protocol was approved by a Medical Ethics Committee (Stichting Beoordelings Ethiek Biomedisch Onderzoek, Assen, The Netherlands) prior to the start of the clinical phase. Participants gave written informed consent before any study-related procedures were undertaken.

#### Study design and participants

This was an open-label interventional study. In total 30 nonsmoking, healthy males (Fitzpatrick skin type I-III), aged 18 to 45 years, were included. Participants with any immune disease or recent infection were excluded. Twenty-four (24) participants received a two-and-a-half-day twice daily (b.i.d.) pretreatment with topical clobetasol propionate 0.05% ointment on a designated area on the volar forearm prior to LPS administration (5 ng LPS in 50 µL 0.9% sodium chloride (NaCl) per injection), and 6 participants received a two-and-a-half-day b.i.d. pretreatment with oral prednisolone dosed at 0.25 mg/kg body weight per administration prior to LPS administration. On the day of LPS administration participants received the final administration of clobetasol or prednisolone. The contralateral volar forearm of the participants treated with clobetasol served as untreated control. Participants received one treatment regimen of either 0, 2, or 4 intradermal LPS injections (5 ng LPS in 50 µL 0.9% NaCl solution). See Figure 1 for a graphical display of the study design. In order to minimize any possible effects of the circadian rhythm on the response to LPS, LPS injections took place between 9:00 and 11:00 for clobetasol-treated participants, and between 9:30 and 10:00 (3 participants) and 12:20 and 12:50 (3 participants) for prednisolone treated participants.

#### Skin assessments

The skin was evaluated before dosing and at 3, 6, 10, 24, and 48 hours after LPS administration. Erythema was assessed by multispectral photo analysis (Antera 3D, Miravex, Ireland), perfusion by laser speckle contrast imaging (LSCI; PeriCam PSI System, Perimed Jäfàlla, Sweden), and temperature by thermography camera FLIR X6540sc (FLIR Systems Inc., Breda, The Netherlands). All skin assessments were performed in a climate-controlled room with temperature between 19 and 21 degrees Celsius. At the indicated timepoints (Table S1) a suction blister was raised over the marked injection site or untreated (baseline) area. The induction of suction blisters was performed according to the method published by Motwani et al.\(^7\) The performance of a suction blister would disqualify that area for further follow-up with noninvasive measurements.

#### Suction blisters

Blister fluid was collected in a V-bottom plate containing 50 µL 3% sodium citrate (Sigma, St. Louis, Missouri) in phosphate-buffered saline (PBS) (Gibco, Waltham, Massachusetts) and kept on ice. The plate was centrifuged, and supernatant was weighed to estimate the volume and then frozen at −80°C for cytokine analysis (Meso Scale Discovery, Rockville, Maryland); the following cytokines were analyzed: interleukin 1β (IL-1β), IL-6, IL-8, IL-10, interferon-γ (IFN-γ), and tumor necrosis factor (TNF). Samples below the lower limit of quantification (LLOQ) were replaced by 0.5 × LLOQ. Please refer to Table S2 for an overview of samples above LLOQ. The pellet was resuspended in RoboSep buffer (Stemcell, Vancouver, Canada). A cocktail of fluorescent antibodies for cell surface markers was added to the cells and incubated for 30 minutes on ice. stained samples were washed with PBS and measured with a MACSQuant 10 (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Flow cytometry data were analyzed with Flowlogic 7.1 (Inivai, Mentone, Australia). Parallel to the blister fluid, peripheral blood was collected by venepuncture in a sodium heparin vacutainer (BD, Franklin Lakes, New Jersey). One hundred microliters whole blood was treated with red blood cell lysis buffer (bioscience, Waltham, Massachusetts) and washed with PBS and resuspended in RoboSep buffer. Staining was similar to previously mentioned blister cells. The following antibodies were used: CD4 PerCP (clone OKT4 catalog [cat. No. 317432, BioLegend, San Diego, California]), CD8 BV510 (clone SK1 cat No. 344732, BioLegend), CD56 PE-Cy7 (clone MEM-188, cat. No. 304628, BioLegend), CD14 BV421 (clone M5E2, cat. No. 301830, BioLegend), CD16 APC-Cy7 (clone 3G8, cat. No. 302018, BioLegend), CD19 FITC (clone HIB19, cat. No. 302062, BioLegend), CD20 FITC (clone 2H7, cat. No. 302304, BioLegend), HLA-DR PE (clone REA805, cat. No. 130-111-789, Miltenyi Biotec). Cell populations were classified based on the following profile: SSChighHLA-DRCD16− neutrophils,
HLA-DR⁺CD14⁺CD16⁻ classical monocytes, HLA-DR⁺CD14⁺CD16⁺ intermediate monocytes, HLA-DR⁺CD14⁻CD16⁻ nonclassical monocytes, HLA-DR⁺CD14⁻CD16⁺ dendritic cells, HLA-DR⁻CD56⁺ NK Cells, HLA-DR⁻CD3⁺ T cells, and HLA-DR⁺CD19⁺CD20⁺ B cells. An overview of the gating strategy can be found in Figure S1.

**Statistics**

Repeatedly measured end points were analyzed with a mixed model of variance with fixed factors treatment, time after LPS, and treatment by time after LPS, and random factor subject. If applicable (nonblister parameters) the baseline value (prior to LPS administration) was used as covariate. The following contrasts were calculated within the models: clobetasol propionate vs. untreated control (crossover), and prednisolone vs. untreated control (parallel). All calculations were performed using SAS for windows V9.4 (SAS Institute, Inc., Cary, NC). Outcomes were not adjusted for multiple testing due to the exploratory nature of this study.

**RESULTS**

**Topical and systemic corticosteroids reduce LPS-driven immune cell infiltration**

We have previously shown that the cellular response to intradermal LPS can be successfully studied using suction blisters. In this study, suction blisters were induced at the indicated timepoints according to Table S1. On average, each blister contained ~20 to 40 microliters of blister fluid (data not shown). An overview of the different subsets characterized by flow cytometry is shown in Table S3. In the absence of corticosteroid treatment, LPS administration led to a rapid influx of neutrophils (SSC<sup>hi</sup>HLA-DR⁻CD16⁻) 6 hours after LPS administration (Figure 4a), which declined to almost baseline levels at 48 hours. CD14⁺CD16⁻ mononuclear phagocytes (“classical monocytes”) and CD14⁺CD16⁺ mononuclear phagocytes (“intermediate monocytes”) peaked at 24 hours (Figure 4b,c), followed by CD14⁻CD16⁺ mononuclear phagocytes (“nonclassical monocytes”) and dendritic cells (HLA-DR⁻CD14⁻CD16⁻) which were already present at 24 hours but peaked 48 hours after LPS administration (Figure 4d,e). NK-cell (HLA-DR⁻CD56⁻) and T-cell (HLA-DR⁻CD3⁺) influx was highest 24 hours after LPS but remained relatively high 48 hours with LPS injection on untreated skin (“control”). (Figure 3a–c).

In addition, clobetasol treatment also statistically significant reduced the LPS-driven inflammatory response of the skin from baseline through 48 hours (erythema 95% CI: −0.10, −0.03; temperature 95% CI: −0.18, −0.01; perfusion 95% CI: −10.46, −3.71), compared with prednisolone (Figure 3a–c).

Table 1 provides an overview of the statistical analysis of skin temperature, perfusion, and erythema.

![Figure 1](image-url) Graphical display of the study design. Participants were pretreated with either topical clobetasol or oral prednisolone at 0.25 mg/kg body weight for two-and-a-half days prior to LPS administration. Follow-up took place 3, 6, 10, 24, and 48 hours after LPS administration. b.i.d., twice daily; i.d., intradermal; LPS, lipopolysaccharide.
after LPS (Figure 4f,g). LPS did not cause a significant B-cell (HLA-DR+CD19+CD20+) response (Figure 4h). Pretreatment with clobetasol significantly suppressed the influx of all studied inflammatory cells (Figure 4b–g) except for neutrophils (Figure 4a) and B cells (Figure 4h). Prednisolone showed a comparable anti-inflammatory effect, although not statistically significant, most likely because of a lack of power due to the parallel statistical analysis (compared with crossover statistical analysis for clobetasol) and fewer participants. The neutrophil influx was unaffected by prednisolone treatment (Figure 4a). Prednisolone pretreatment led to a statistically significant increase (P < 0.0001), in contrast to other immune cell subsets, in amount of B cells found in the blister exudate (Figure 4h). B cells were already present in high levels at baseline and were not affected by LPS administration. It is unknown whether there is a true physiological basis behind the B-cell influx.

**Topical or systemic corticosteroids do not affect LPS-driven cytokine responses**

In addition to the dermal cellular immune response, cytokine levels were measured in blister exudate. LPS administration drove a strong cytokine response, detectable 6 hours after LPS administration, consisting of IL-1β, IL-6, IL-8, IL-10, IFN-γ, and TNF (Figure 5a–f). At 48 hours after LPS administration, cytokine levels were back at baseline levels (Figure 5a–f). Clobetasol and prednisolone pretreatment did not substantially alter the cytokine response to LPS administration (Figure 5a–f). No statistical analysis was performed for the contrast between control, clobetasol, and prednisolone due to the large number of samples with cytokine levels below the LLOQ, at baseline, and at the 24 and 48 hour timepoints. A visual inspection of the data suggests that prednisolone and clobetasol suppressed the IFN-γ response to LPS (Figure 5e), whereas clobetasol caused a trend toward an increase in IL-1β and IL-6 response to LPS (Figure 5a–b).
DISCUSSION

The aim of this study was to validate our previously established intradermal LPS model with the known anti-inflammatory corticosteroids administered as topical clobetasol propionate 0.05% ointment and oral prednisolone, and to provide mechanistic insights into the local mode of action of both corticosteroids. Both anti-inflammatory drugs suppressed the objectified clinical response to LPS in terms of local skin temperature, perfusion, and erythema. A power calculation was performed which showed that in a parallel study design a sample size of eight participants per treatment group with five post-LPS measurements would provide 80% power for a minimum detectable effect size of 11.6 arbitrary units (AU) for LSCI. Likewise, a sample size of 12 would provide 80% power for a minimum detectable effect size of 9.2 AU. The maximum LPS response was 40.9 AU ± 15.1 (mean and SD) as measured by LSCI and occurred at 24 hours after injection. The LPS-induced clinical response is likely partially mediated through inducible nitric oxide synthase (iNOS) leading to nitric oxide production and subsequent dermal vasodilation.10,11 Corticosteroids are known inhibitors of iNOS,12 and Faurschou et al. demonstrated in a clinical trial that topical corticosteroids reduce iNOS-mediated vasodilation.13,14 Both glucocorticoids also inhibited the dermal inflammatory cell influx in response to LPS, measured in suction blister fluid: the attraction of monocytes, dendritic cells, NK cells, and T cells was suppressed under corticosteroid treatment. Interestingly, the neutrophil influx remained unaffected by topical or systemic glucocorticoid pretreatment. Glucocorticoids exert both pro-inflammatory and anti-inflammatory effects on neutrophils which, as summarized by Ronchetti et al., can sometimes seem contradictory.15 Glucocorticoids enhance the mobilization of neutrophils from the bone marrow into the circulation, and reduce the expression of adhesion molecules such as L-selectin (CD62L) on neutrophils and adhesion molecules such as ICAM-1 on the endothelium.15,16 The net result is neutrophilia which was also present at baseline in our participants receiving prednisolone (data not shown). In line with this, glucocorticoids may impair the capacity of neutrophils to extravasate into inflamed tissue,7 but in the present study the recruitment of neutrophils was unaffected (Figure 4a). Neutrophils, as we have already shown during the earlier characterization of the intradermal LPS model, are the first cells to arrive in response to LPS,5,6 and it is known that neutrophils play a central role in orchestrating the acute immune response.17 The fact that we did not observe a
Figure 4. Topical and systemic corticosteroids reduced the LPS-driven immune cell infiltration. (a) Neutrophils (b) Classical monocytes (c) Intermediate monocytes (d) Nonclassical monocytes (e) Dendritic cells (f) Natural killer cells (g) T cells (h) B cells. Immune cells were quantified in blister exudate by flow cytometry at different timepoints after LPS administration. Data are presented as mean ± SEM. *P < 0.05, **P = 0.001, and ***P < 0.0001. Prednisolone showed a comparable anti-inflammatory effect, although not statistically significant, likely because of a lack of power due to the parallel analysis and fewer participants than clobetasol vs. control. LPS, lipopolysaccharide; NK, natural killer.
reduction in neutrophil infiltration but did observe a reduction of all other immune cell subsets gave rise to our hypothesis that corticosteroid pretreatment did not affect the capacity of stromal cells and local immune cells to initiate neutrophil attraction but did lead to a reduced capacity of arriving neutrophils to further drive the acute immune response. A future study should focus not only on neutrophil recruitment and cell count but also investigate neutrophil function and activation status at the site of inflammation. Another finding was that pretreatment with clobetasol or prednisolone did not result in an obvious reduction in the LPS-induced cytokine response (Figure 5). One could argue that the absence of such an inhibiting effect may relate to sample timing. The earliest blister assessment was made at 6 hours after LPS, which in theory may have been too late to cover the acute neutrophil response. We did not include an earlier timepoint that possibly could have shown a reduced response, or that could have shown a delay in peak response, whereas the clinical outcome measures (skin temperature, skin perfusion, and erythema) show a corticosteroid effect as early as 3 hours after LPS injection. However, our findings are supported by the work of Bartko et al., who observed that dexamethasone suppressed the systemic response to instilled LPS but was unable to significantly suppress the local release of IL-6, IL-8, and TNF in humans.8 Another possible explanation could be that due to the small blister volume and low cytokine concentrations, results are more likely to fall below the detection limit, which makes it difficult to observe subtle changes between treatment and control. Our data demonstrate that attracted monocytes and lymphocytes are probably minor contributors to the local cytokine response, and

**Figure 5** Topical and systemic corticosteroids do not affect the LPS-driven cytokine responses. (a) IL-1β (b) IL-6 (c) IL-8 (d) IL-10 (e) IFN-γ (f) TNF. Cytokine concentrations in blister exudate were analyzed by MSD. Data are presented as mean ± SD. IL, interleukin; IFN-γ, interferon-γ; MSD, meso scale discovery; TNF, tumor necrosis factor.
supposedly skin-resident immune cells such as dendritic cells, macrophages, keratinocytes, and fibroblasts are the primary source of LPS-driven cytokines. Interestingly, all these cell types have been described to be sensitive to the anti-inflammatory effects of corticoids in vitro; therefore it is intriguing to find in our study that corticosteroid treatment did not suppress cytokine production in vivo. Given the fact that we used conventional therapeutic corticosteroid doses that, in the case of prednisolone, led to systemic anti-inflammatory activity, and based on the significant inhibition of local perfusion, erythema, and temperature, it is unlikely that the local drug exposure was too low to suppress cytokine responses. Our observations suggest that follow-up investigations on the mechanisms behind the LPS-driven tissue response, and the effects of corticosteroids herein should be explored further. In particular, the apparent discrepancy between the convincing corticosteroid effects on clinical symptoms (LPS-driven perfusion, erythema, and temperature increase) and immune cell attraction (monocytes, DCs, NK cells, and lymphocytes) on one hand, and the lack of a significant inhibitory effect on local cytokine production and neutrophil influx on the other hand, is an important observation that may change the mechanistic thinking on corticosteroid effects in inflammatory skin diseases.

In conclusion, in this present study we have successfully demonstrated that both topical and systemic corticosteroid pretreatment are effective in suppressing the classical hallmarks of LPS-induced dermal inflammation (erythema, heat, and perfusion) and that the suppressed inflammatory response can also be quantified by a reduction in inflammatory cell attraction. These findings support the use of the intradermal LPS model for future proof-of-mechanism studies as well as profiling studies of novel anti-inflammatory compounds.

SUPPORTING INFORMATION
Supplementary information accompanies this paper on the Clinical Pharmacology & Therapeutics website (www.cpt-journal.com).

FUNDING
Cutanea Life Science, Inc., Wayne, Pennsylvania, USA.

CONFLICT OF INTEREST
Gary Feiss was employed by Cutanea Life Sciences during the execution of the study. All other authors declared no competing interests for this work.

AUTHOR CONTRIBUTIONS

©2021 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.